{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:48:44Z","timestamp":1771667324802,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jiph.2020.07.018","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T05:51:02Z","timestamp":1598421062000},"page":"1589-1591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals"],"prefix":"10.1016","volume":"13","author":[{"given":"Wadha","family":"Alfouzan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar S.","family":"Boswihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edet","family":"Udo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2020.07.018_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/TCRM.S75412","article-title":"Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia","volume":"1","author":"Mpenge","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jiph.2020.07.018_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/sur.2015.209","article-title":"Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers","volume":"17","author":"Sader","year":"2016","journal-title":"Surg Infect"},{"issue":"6","key":"10.1016\/j.jiph.2020.07.018_bib0015","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1128\/AAC.00088-14","article-title":"Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-non susceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations","volume":"58","author":"Werth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiph.2020.07.018_bib0020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2020.07.018_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2020.07.018_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/1120009X.2018.1438768","article-title":"Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait","volume":"30","author":"Jamal","year":"2018","journal-title":"J Chemotherapy"},{"key":"10.1016\/j.jiph.2020.07.018_bib0035","series-title":"M100-S24 Performance standards for antimicrobial susceptibility testing: 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.jiph.2020.07.018_bib0040","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","article-title":"Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2020.07.018_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.5578\/mb.5479","article-title":"In vitro activity of ceftaroline to MRSA isolates: a multicenter study","volume":"47","author":"Mengelo\u011flu","year":"2013","journal-title":"Mikrobiyol Bul"},{"key":"10.1016\/j.jiph.2020.07.018_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3855\/jidc.7196","article-title":"Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India","volume":"10","author":"Bakthavatchalam","year":"2016","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jiph.2020.07.018_bib0055","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.04068-14","article-title":"Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998","volume":"59","author":"Kelley","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2020.07.018_bib0060","first-page":"3259","article-title":"Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg\/L breakpoint","volume":"70","author":"Livermore","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2020.07.018_bib0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/JCM.05395-11","article-title":"First comprehensive evaluation of the M.I.C. Evaluator device compared to Etest and CLSI broth microdilution for MIC testing of aerobic Gram-positive and Gram-negative bacterial species","volume":"50","author":"Rennie","year":"2012","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:08:00Z","timestamp":1761750480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034120305979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1876034120305979"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2020.07.018","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2020.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}